• FDA Approves Keytruda for Liver Cancer Patients Who Had Received Nexavar
  • FDA Approves Keytruda-Chemotherapy Combo as First-line Therapy for NSCLC
  • Keytruda Elicits Complete Response in 40% of Group of High-risk Bladder Cancer Patients, Early Phase 2 Trial Data Show
  • CHMP Favors EU Approval of Keytruda for Advanced Melanoma Patients with Complete Tumor Resection
  • SQZ Biotech and Roche Expand Collaboration to Develop Cell Therapies for Cancer Patients
  • Keytruda-Inlyta Combo Extends Survival in Advanced Renal Cell Carcinoma Patients, Phase 3 Trial Shows
  • Immunotherapy Particularly Effective Against Aggressive Hereditary Melanoma, Study Reports
  • Opdivo Fails to Extend Survival in SCLC Patients in Phase 3 Trial, Bristol-Myers Squibbs Reports
  • Opdivo-Yervoy Combo Shows Potential as First-line Treatment for Certain Colorectal Cancers
  • Keytruda Improves Survival in Patients with Relapsed or Metastatic Head, Neck Cancer, Interim Data Show
  • OSE Seeks French Regulatory Approval for Phase 2 Trial of Tedopi in Advanced Pancreatic Cancer
  • Celyad, Horizon Discovery Group Working to Develop New CAR T-cell Therapies